AMENDMENTS

Amendments to the Claims:

Please replace all prior versions and listings of claims with the following Listing of Claims:

1. (Currently Amended) A method for treating Alzheimer's disease comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that specifically binds ~~preferentially~~ to amino acids 28-40 of $Aß_{1-40}$ peptide (SEQ ID NO:1) and a pharmaceutically acceptable carrier, wherein the antibody does not show significant cross-reactivity with $Aß_{1-42}$ and $Aß_{1-43}$ peptide.

2. (Currently Amended) The method of claim 1, wherein the antibody specifically binds ~~preferentially~~ to an epitope that includes amino acid 39 and/or 40 of the $Aß_{1-40}$ peptide (SEQ ID NO:1).

3. (Canceled)

4. (Original) The method of claim 1, wherein the Fab fragment of the antibody binds to $Aß_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

5. (Original) The method of claim 1, wherein the Fab fragment of the antibody binds to $Aß_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

6. (Original) The method of claim 2, wherein the Fab fragment of the antibody binds to $Aß_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

7. (Original) The method of claim 2, wherein the Fab fragment of the antibody binds to $Aß_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

8. (Currently Amended) The method of claim 1, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 to $Aß_{1-40}$ peptide (SEQ ID NO:1).

9. (Currently Amended) The method of claim 1, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 binds.

10. (Previously Presented) The method of claim 1, wherein the antibody is a monoclonal antibody.

11. (Original) The method of claim 1, wherein the antibody is a humanized antibody.

12. (Original) The method of claim 1, wherein the antibody is a human antibody.

13 . (Currently Amended) A method of suppressing formation of amyloid plaques in a subject comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that specifically binds ~~preferentially~~ to amino acids 28-40 of Aß$_{1-40}$ peptide (SEQ ID NO:1) and a pharmaceutically acceptable carrier, wherein the antibody does not show significant cross-reactivity with Aß$_{1-42}$ and Aß$_{1-43}$ peptide.

14. (Currently Amended) The method of claim 13, wherein the antibody specifically binds ~~preferentially~~ to an epitope that includes amino acid 39 and/or 40 of the Aß$_{1-40}$ peptide (SEQ ID NO:1).

15. (Cancelled)

16. (Original) The method of claim 13, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

17. (Original) The method of claim 13, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

18. (Original) The method of claim 14, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

19. (Original) The method of claim 14, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

20. (Currently Amended) The method of claim 13, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 to Aß$_{1-40}$ peptide (SEQ ID NO:1).

21. (Currently Amended) The method of claim 13, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 binds.

22. (Previously Presented) The method of claim 13, wherein the antibody is a monoclonal antibody.

23. (Original) The method of claim 13, wherein the antibody is a humanized antibody.

24. (Original) The method of claim 13, wherein the antibody is a human antibody.

25. (Original) The method of claim 13, wherein the amyloid plaques are in the brain of the subject.

26. (Currently Amended) A method of reducing amyloid plaques in a subject comprising administering to a subject an effective amount of a pharmaceutical composition comprising an antibody that specifically binds ~~preferentially~~ to amino acids 28-40 of Aß$_{1-40}$ peptide (SEQ ID NO:1) and a pharmaceutically acceptable carrier, wherein the antibody does not show significant cross-reactivity with Aß$_{1-42}$ and Aß$_{1-43}$ peptide.

27. (Currently Amended) The method of claim 26, wherein the antibody specifically binds ~~preferentially~~ to an epitope that includes amino acid 39 and/or 40 of the Aß$_{1-40}$ peptide (SEQ ID NO:1).

28. (Cancelled)

29. (Original) The method of claim 26, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

30. (Original) The method of claim 26, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

31. (Currently Amended) The method of claim ~~26~~ 27, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 200 nM or less.

32. (Original) The method of claim 27, wherein the Fab fragment of the antibody binds to Aß$_{1-40}$ peptide (SEQ ID NO:1) with an affinity of about 1 nM or less.

33. (Currently Amended) The method of claim 26, wherein the antibody competitively inhibits binding of a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 to Aß$_{1-40}$ peptide (SEQ ID NO:1).

34. (Currently Amended) The method of claim 26, wherein the antibody binds to the same epitope to which a monoclonal antibody comprising the amino acid ~~sequence~~ sequences of ~~SEQ ID NO:4~~ SEQ ID NOs:4 and 6 binds.

35. (Previously Presented) The method of claim 26, wherein the antibody is a monoclonal antibody.

36. (Original) The method of claim 26, wherein the antibody is a humanized antibody.

37. (Original) The method of claim 26, wherein the antibody is a human antibody.

38. (Original) The method of claim 26, wherein the amyloid plaques are in the brain of the subject.

39-50. (Cancelled)

51. (Previously Presented) The method of claim 1, wherein the subject is a human.

52. (Previously Presented) The method of claim 13, wherein the subject is a human.

53. (Previously Presented) The method of claim 26, wherein the subject is a human.

54. (Cancelled)